Literature DB >> 7795613

Prognostic determinants in lupus nephritis: a long-term clinicopathologic study.

J V Donadio1, G M Hart, E J Bergstralh, K E Holley.   

Abstract

Over the past 50 years, survival has improved in patients with systemic lupus erythematosus and associated nephritis. Yet, there are few long-term outcome studies in patients with well-defined nephropathy. We examined the outcome of 439 patients with lupus nephritis who were seen at the Mayo Clinic between 1964 and 1986 in whom renal biopsies were assessed using the World Health Organization (WHO) classification. There were 341 women and 98 men (mean +/- s.d., age 33.5 +/- 14 years); 200 (46%) patients were hypertensive and 249 (57%) had impaired renal function at renal biopsy. All WHO morphologic classes were represented and 339 (77%) patients had class III, IV and V (the more severe forms of nephritis). Follow-up averaged 10.2 years per patient. At last contact, 286 (65%) patients were alive and 153 (35%) were dead. Overall patient survival was 80%, 69% and 53% at 5, 10 and 20 years after biopsy that was significantly worse than expected survival (P < 0.001). Ten-year cumulative patient survival improved comparing earlier to more recent time spans: 64% in 231 patients seen during 1964-75; 76% in 2089 patients studied during 1976-86 (P = 0.03). Survival free of renal failure was 83%, 74% and 64% at 5, 10 and 20 years, and survival was unfavorably influenced by progressive WHO class, hypertension, impaired renal function, nephrotic range proteinuria, hypoalbuminemia and anemia. Multivariate analysis found impaired renal function, increased urine protein, anemia and younger age to be independent predictors of renal failure. WHO class was not a significant predictor when adjusted for these four factors. Cardiovascular events accounted for 48% of the known deaths and were equally distributed across all WHO classes, followed by infections, renal failure, malignancy, respiratory failure and gastrointestinal bleeding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795613     DOI: 10.1177/096120339500400206

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  32 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  Identification and validation of lupus nephritis cases using administrative data.

Authors:  L B Chibnik; E M Massarotti; K H Costenbader
Journal:  Lupus       Date:  2010-02-23       Impact factor: 2.911

Review 3.  Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Authors:  Juan-Manuel Anaya; Carlos Cañas; Rubén D Mantilla; Ricardo Pineda-Tamayo; Gabriel J Tobón; Catalina Herrera-Diaz; Diego M Rendón; Adriana Rojas-Villarraga; Mauricio Uribe
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

4.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

5.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

Review 6.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 7.  Overview of pathophysiology and treatment of human lupus nephritis.

Authors:  Kimberly Trotter; Marcus R Clark; Vladimir M Liarski
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

8.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Authors:  Abdurahman Saud Al Arfaj; Najma Khalil; Salman Al Saleh
Journal:  Rheumatol Int       Date:  2009-04-21       Impact factor: 2.631

9.  Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).

Authors:  Meral Calguneri; Zeynep Ozbalkan; M Akif Ozturk; Sule Apras; A Ihsan Ertenli; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

10.  Lupus nephritis in childhood: a review of 53 patients followed at a single center.

Authors:  Radovan Bogdanović; Vesna Nikolić; Srdjan Pasić; Jovan Dimitrijević; Jasmina Lipkovska-Marković; Jelena Erić-Marinković; Milos Ognjanović; Aleksandra Minić; Natasa Stajić
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.